ADMA Begin Period Cash Flow from 2010 to 2024
| ADMA Stock | USD 17.72 1.26 6.64% |
Begin Period Cash Flow | First Reported 2006-12-31 | Previous Quarter 45.3 M | Current Value 88.2 M | Quarterly Volatility 26.3 M |
Check ADMA Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADMA Biologics' main balance sheet or income statement drivers, such as Interest Expense of 26.3 M, Other Operating Expenses of 248.4 M or Operating Income of 22.7 M, as well as many indicators such as Price To Sales Ratio of 3.72, Dividend Yield of 0.0694 or PTB Ratio of 7.86. ADMA financial statements analysis is a perfect complement when working with ADMA Biologics Valuation or Volatility modules.
ADMA | Begin Period Cash Flow |
Latest ADMA Biologics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of ADMA Biologics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. ADMA Biologics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ADMA Biologics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
ADMA Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 32,573,448 | |
| Geometric Mean | 11,826,755 | |
| Coefficient Of Variation | 87.46 | |
| Mean Deviation | 22,682,761 | |
| Median | 26,149,477 | |
| Standard Deviation | 28,489,934 | |
| Sample Variance | 811.7T | |
| Range | 90.8M | |
| R-Value | 0.82 | |
| Mean Square Error | 286.7T | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | 5,222,366 | |
| Total Sum of Squares | 11363.5T |
ADMA Begin Period Cash Flow History
About ADMA Biologics Financial Statements
ADMA Biologics stakeholders use historical fundamental indicators, such as ADMA Biologics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although ADMA Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ADMA Biologics' assets and liabilities are reflected in the revenues and expenses on ADMA Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ADMA Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 86.5 M | 90.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out the analysis of ADMA Biologics Correlation against competitors. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.